| Identification | Back Directory | [Name]
Ethanesulfonamide, N-[6-(6,7-dihydro-1-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-3-yl)-1-(1,1-di-2-pyridinylethyl)-1H-indol-4-yl]- | [CAS]
2344825-52-9 | [Synonyms]
Ethanesulfonamide, N-[6-(6,7-dihydro-1-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-3-yl)-1-(1,1-di-2-pyridinylethyl)-1H-indol-4-yl]- | [Molecular Formula]
C30H28N6O3S | [MOL File]
2344825-52-9.mol | [Molecular Weight]
552.65 |
| Hazard Information | Back Directory | [Description]
XL-223 is a potent BET inhibitor effective in endocrine-resistant ER+ breast cancer with acquired resistance to fulvestrant and palbociclib. XL-223 was more potent in MCF-7:CFR cells than six BET inhibitors in clinical trials. Transcriptomic analysis differentiated XL-223 from the benchmark BETi, JQ-1, showing downregulation of oncogenes and upregulation of tumor suppressors and apoptosis. The therapeutic approach was validated by oral administration of XL-223 in orthotopic xenografts of endocrine-resistant breast cancer in monotherapy and in combination with fulvestrant. Importantly, at an equivalent dose in rats, thrombocytopenia was mitigated. |
|
|